Roivant’s pulmonary hypertension drug shines with ‘blowout’ Phase 2 data

Mosliciguat, being developed by the Roivant Sciences subsidiary Pulmovant, ‘significantly exceeded expectations’ in reducing pulmonary vascular resistance, according to analysts, and is progressing to a late-stage study.